Trial reportPediatric pulmonology2025
HHHFNC Versus NIPPV Delivered by Long Narrow Cannula in Preterm Infants: Randomized Noninferiority Trial.
Trial report in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHeated humidified high flow (HHHFNC) and nasal intermittent positive pressure ventilation (NIPPV) delivered by cannula with long and narrow tubing (CLNT) are increasingly used in preterm infants for providing noninvasive respiratory support, due to their high comfort level and minimal nasal trauma. Despite their widespread use, no randomized controlled trial has been conducted so far.
objectiveDetermine whether HHHFNC is non-inferior to CLNT-NIPPV in providing respiratory support for preterm infants. STUDY
designAn unblinded, randomized controlled, non-inferiority multicenter trial. METHODOLOGY: Preterm infants randomized to either HHHFNC or CLNT-NIPPV. Infants born > 28 weeks of gestation were eligible to enter the study either as primary treatment after birth or post-extubation. Infants born ≤ 28 weeks of gestation were only eligible post-extubation. The primary outcome was treatment failure within 7 days.
resultsOne hundred and thirty infants were enrolled in the study; 65 in each group. Most (82%) were > 28 weeks, and primary treatment (73%). HHHFNC was non-inferior to CLNT-NIPPV in the primary outcome which occurred in 12.3% compared to 23.0% of the infants, respectively (risk difference (RD) -10.77%, 95% CI of RD -23.7 to 2.22 [within the non-inferiority margin], χ
conclusionsIn this study of preterm infants mostly > 28 weeks of gestation, HHHFNC was non-inferior to CLNT-NIPPV in providing respiratory support, and caused less nasal trauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.